Adaptive Radiotherapy Compared With Standard Image-Guided Radiotherapy for Cervical Cancer
Tests online adaptive radiotherapy in adults with cervical cancer receiving radical radiation treatment.
Plain-language title generated from the registry record
Registry title: Online Adaptive Radiotherapy for Cervical Cancer
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18-80 with cervical squamous cell cancer who are about to start radical radiotherapy with chemotherapy given at the same time.
- Age
- 18-80 years
- Sex
- Women only
- Disease stage
- Cervical squamous cell cancer confirmed by tissue examination, 2018 FIGO stage Ib3, II, IIIB or IIIC1.
- Earlier treatment
- Must not have had radiotherapy or chemotherapy before. Must not have had radical surgery for cervical cancer. Radical pelvic radiotherapy with platinum-based chemotherapy (cisplatin or carboplatin alone) is planned.
Main reasons for not taking part
- Earlier radiotherapy or chemotherapy
- Earlier radical surgery for cervical cancer
- A past history of another cancer
- Pregnant or breastfeeding
- Other serious poorly controlled illnesses (heart, urinary, digestive, lung, blood or brain and nerve diseases)
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06562166, who can take part
Where in China
- Peking Union Medical College HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking Union Medical College Hospital
- Trial code
- NCT06562166
- Record updated
- 8 January 2026
- Original description
This study aims to evaluate the clinical efficacy and safety of online adaptive radiotherapy for cervical cancer patients received radical radiotherapy. By comparing with image-guided radiotherapy, the study explores the potential advantages of online adaptive radiotherapy in reducing treatment toxicity and improving local control.Read full original descriptionShow less
Online Adaptive Radiotherapy (oART) in Radical Radiotherapy for Cervical Cancer - A Multi-center Randomized Controlled Study
This study aims to evaluate the clinical efficacy and safety of online adaptive radiotherapy for cervical cancer patients received radical radiotherapy. By comparing with image-guided radiotherapy, the study explores the potential advantages of online adaptive radiotherapy in reducing treatment toxicity and improving local control.
Inclusion: 18-80 years old; Pathologically confirmed diagnosis of cervical cancer and pathological type of cervical squamous carcinoma; 2018 FIGO Stage Ib3, II, IIIB and IIIC1; Proposed radical pelvic radiotherapy + concurrent sensitizing chemotherapy (platinum-based (cisplatin 30-40mg/m2 or carboplatin alone), starting concurrently in the first week, ≥5 courses); ECOG score 0-2; Life expectancy greater than 6 months; Ability to remain lying down for more than 30 minutes; Patients were fully voluntary and autonomous and co-operated in signing the study informed consent form; Complete blood count and basal metabolic indexes within 14 days before enrolment must meet the following requirements: NEUT ≥ 1.5*109/L, HGB ≥ 60g/L, platelets ≥ 100×109/, blood creatinine \<1.5 mg/dL. AST and ALT are within 2 times the upper limit of normal; Must complete baseline assessments and investigations required before treatment before enrolment; be eligible for regular follow-up.
Exclusion: Have received radiotherapy or chemotherapy in the past; Have undergone radical surgery for cervical cancer; Have a previous history of malignant tumor; Presence of other serious co-morbidities such as poorly controlled cardiovascular, urinary, digestive, respiratory, hematological and central nervous system diseases; Pregnant or lactating women.